Cargando…

Utility of adjuvant systemic therapy in melanoma

The lack of effective drugs in stage IV melanoma has impacted the effectiveness of adjuvant therapies in stage II/III disease. To date, chemotherapy, immunostimulants and vaccines have been used with minimal success. Interferon (IFN) has shown an effect on relapse-free survival (RFS) in several clin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eggermont, A. M. M., Testori, A., Marsden, J., Hersey, P., Quirt, I., Petrella, T., Gogas, H., MacKie, R. M., Hauschild, A.
Formato:	Texto
Lenguaje:	English
Publicado:	Oxford University Press 2009
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2712588/ https://www.ncbi.nlm.nih.gov/pubmed/19617295 http://dx.doi.org/10.1093/annonc/mdp250

Ejemplares similares

Epidemiology of invasive cutaneous melanoma
por: MacKie, R. M., et al.
Publicado: (2009)

Biomarkers in melanoma
por: Gogas, H., et al.
Publicado: (2009)

Surgery and radiotherapy in the treatment of cutaneous melanoma
por: Testori, A., et al.
Publicado: (2009)

Adjuvant therapy for high-risk melanoma
por: Eggermont, Alexander M.M.
Publicado: (2013)

Small molecules and targeted therapies in distant metastatic disease
por: Hersey, P., et al.
Publicado: (2009)

Hormone replacement therapy after surgery for stage 1 or 2 cutaneous melanoma
por: MacKie, R M, et al.
Publicado: (2004)

Single-agent interleukin-2 in the treatment of metastatic melanoma
por: Petrella, T., et al.
Publicado: (2007)

Human Malignant Melanoma
por: MacKie, R. M.
Publicado: (1979)

Cutaneous malignant melanoma in Scotland.
por: MacKie, R. M., et al.
Publicado: (1982)

Adjuvant Therapy for Melanoma: Past, Current, and Future Developments
por: Testori, Alessandro A. E., et al.
Publicado: (2020)

What is changing in the adjuvant treatment of melanoma?
por: Ascierto, Paolo A., et al.
Publicado: (2017)

Cerebral metastases of cutaneous melanoma.
por: Gupta, G., et al.
Publicado: (1997)

Severe sunburn and subsequent risk of primary cutaneous malignant melanoma in scotland.
por: MacKie, R. M., et al.
Publicado: (1982)

Staging of cutaneous melanoma
por: Mohr, P., et al.
Publicado: (2009)

Comparison between lentigo maligna melanoma and other histogenetic types of malignant melanoma of the head and neck. Scottish Melanoma Group.
por: Cox, N. H., et al.
Publicado: (1996)

What can we learn from phase II adjuvant trials in melanoma?
por: Keilholz, U, et al.
Publicado: (2000)

Telomerase activity in melanoma and non-melanoma skin cancer
por: Parris, C N, et al.
Publicado: (1999)

Surgical management of melanoma: an EORTC Melanoma Group survey
por: Testori, A, et al.
Publicado: (2013)

Melanoma incidence and mortality in Scotland 1979–2003
por: MacKie, R M, et al.
Publicado: (2007)

Immunotherapy of distant metastatic disease
por: Schadendorf, D., et al.
Publicado: (2009)

Prognostic models for subgroups of melanoma patients from the Scottish Melanoma Group database 1979-86, and their subsequent validation.
por: MacKie, R. M., et al.
Publicado: (1995)

Adjuvant Therapy: Melanoma
por: Davar, Diwakar, et al.
Publicado: (2011)

The role of human melanoma cell ICAM-1 expression on lymphokine activated killer cell-mediated lysis, and the effect of retinoic acid
por: Alexander, C L, et al.
Publicado: (1999)

An update on adjuvant systemic therapies in melanoma
por: Samuel, Evangeline, et al.
Publicado: (2019)

Adjuvant interferon alfa for melanoma: new evidence-based treatment recommendations?
por: Hauschild, A.
Publicado: (2009)

Systemic adjuvant therapy for high-risk cutaneous melanoma
por: Kobeissi, Iyad, et al.
Publicado: (2022)

A comparative study of the relative sensitivity and specificity of radiolabelled monoclonal antibody and computerised tomography in the detection of sites of disease in human malignant melanoma.
por: Elliott, A. T., et al.
Publicado: (1989)

Adjuvant interferon alpha 2b in high risk melanoma – the Scottish study
por: Cameron, D A, et al.
Publicado: (2001)

Adjuvant therapy of melanoma with interferon: lessons of the past decade
por: Ascierto, Paolo A, et al.
Publicado: (2008)

Tumours of the Epidermis
por: MacKie, R.M.
Publicado: (1992)

Prognostic significance of the sequential detection of circulating melanoma cells by RT–PCR in high-risk melanoma patients receiving adjuvant interferon
por: Gogas, H, et al.
Publicado: (2002)

Adjuvant and neoadjuvant therapies in melanoma
por: Lim, Kok Haw Jonathan, et al.
Publicado: (2020)

Adjuvant Treatment of Melanoma
por: Moreno Nogueira, J. A., et al.
Publicado: (2013)

The pharmacokinetic advantages of isolated limb perfusion with melphalan for malignant melanoma.
por: Scott, R. N., et al.
Publicado: (1992)

The “Great Debate” at Melanoma Bridge 2022, Naples, December 1st–3rd, 2022
por: Ascierto, Paolo A., et al.
Publicado: (2023)

Reply to letter by Drs Gillis and Hole
por: MacKie, R. M., et al.
Publicado: (1982)

Strength-based leadership coaching in organizations: an evidence-based guide to positive leadership development
por: MacKie, Doug
Publicado: (2016)

Deselecting Melanoma Patients for Sentinel Lymph Node Biopsy During COVID-19: Clinical Utility of Tumor Molecular Profiling
por: Meves, Alexander, et al.
Publicado: (2020)

Combined targeted therapy and immunotherapy in the treatment of advanced melanoma
por: Wilmott, James S., et al.
Publicado: (2012)

Cost–Utility Analysis of Nivolumab in Adjuvant Treatment of Melanoma in France
por: Bregman, Bruno, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vcka8irec75f9aefh3qt9pqa6g